Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Prusogliptin (DBPR108) in Type 2 Diabetes
NCT05146869Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of prusogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Peak plasma concentration, Area under the plasma concentration versus time curve and 5 more. Started Dec 2021; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05146869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146869.